Study guide

11.1 Hematopoietic Stem Cell Transplantation

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

11.1 Hematopoietic Stem Cell Transplantation

Key Takeaways Explain This Topic AI

Autologous HSCT is the child's own stem cells used as marrow rescue after high-dose chemotherapy and does not cause GVHD; allogeneic HSCT (MSD, MUD, haploidentical, or UCB) reconstitutes marrow and immunity and can provide graft-versus-leukemia.

Pediatric indications include high-risk or relapsed leukemia, severe aplastic anemia, hemoglobinopathies, and immunodeficiencies for allogeneic grafts, and high-risk neuroblastoma for autologous consolidation.

Myeloablative conditioning is more marrow-toxic than reduced-intensity conditioning; busulfan requires seizure prophylaxis and carries SOS/VOD risk, while cyclophosphamide, fludarabine, melphalan, and TBI each have signature injuries.

Engraftment is ANC recovery; bacterial, HSV, and Candida infections dominate before engraftment, CMV and Pneumocystis later, and Aspergillus with prolonged immunosuppression. Protective environment and diet rules are institutional.

Allogeneic GVHD prophylaxis uses calcineurin inhibitors, methotrexate, and often PTCy; acute GVHD hits skin, gut, and liver, while chronic GVHD brings sicca and bronchiolitis. Tender hepatomegaly, weight gain, and jaundice are SOS/VOD (defibrotide)—signpost to the emergency chapter.

Last updated: August 2026

Hematopoietic stem cell transplantation (HSCT) is CPHON Domain III.A.5 and III.B.7. Items test graft type, why a child is transplanted, what conditioning does, when neutrophils return, which infections appear in which window, and the complications that are named here but fully staged later. A 3-year-old finishing induction for high-risk neuroblastoma, a 7-year-old with high-risk AML, and a 9-year-old with severe aplastic anemia and a matched sibling are three different grafts. Mixing autologous marrow rescue with allogeneic graft-versus-leukemia on one consent form is how families leave thinking "bone marrow transplant" is a single procedure.

Autologous versus allogeneic grafts

Autologous HSCT uses the child's own hematopoietic stem cells, collected from peripheral blood after mobilization or, less often, from marrow, cryopreserved, then reinfused after myeloablative high-dose chemotherapy. There is no graft-versus-host disease (GVHD) because the graft is self. There is also no graft-versus-leukemia effect. The point is marrow rescue after otherwise lethal chemotherapy. The pediatric solid-tumor exemplar is high-risk neuroblastoma , often tandem autologous consolidations on contemporary cooperative-group pathways. Selected other relapsed or high-risk solid tumors may use auto HSCT on protocol. Do not import adult myeloma indication lists as pediatric CPHON fact.

Allogeneic HSCT uses another person's hematopoietic stem cells. The graft reconstitutes hematopoiesis and immunity and, in leukemia, can provide graft-versus-leukemia. Name the donor types:

Matched sibling donor (MSD) : an HLA-identical sibling. Preferred when available for many nonmalignant indications and for selected high-risk malignant disease.

Matched unrelated donor (MUD) : a volunteer from a registry, matched at high-resolution HLA.

Haploidentical (haplo) : typically a parent, matched at one haplotype. Post-transplant cyclophosphamide (PTCy) is a common GVHD-prevention platform that made haplo a realistic pediatric option when no MSD or MUD exists.

Umbilical cord blood (UCB) : a banked unit, more permissive HLA mismatch, slower neutrophil recovery, and a longer early-infection window.

  • Graft Source GVHD Typical pediatric use
  • Autologous Child's own cells None (self) High-risk neuroblastoma consolidation; selected solid tumors

Allogeneic MSD HLA-identical sibling Present; lowest among allo Severe aplastic anemia first-line; hemoglobinopathies; immunodeficiencies; high-risk or relapsed leukemia

  • Allogeneic MUD Unrelated registry Present Same indications without an MSD
  • Haploidentical Parent or other half-matched relative Present; PTCy common Expanding option when no MSD or MUD
  • UCB Banked cord unit Present; slower engraftment Alternative graft, especially smaller children
  • Indications you will actually see

High-risk or relapsed leukemia —especially high-risk or relapsed AML , and relapsed or very-high-risk ALL after salvage—is the classic malignant allogeneic indication. Severe aplastic anemia is directed to MSD first-line when a sibling exists (see the marrow-failure section). Hemoglobinopathies , including transfusion-dependent thalassemia and selected sickle cell disease, can be cured by allogeneic HSCT. Primary immunodeficiencies such as severe combined immunodeficiency need immune reconstitution, not another year of supportive transfusions. The solid-tumor sentence to keep is autologous HSCT for high-risk neuroblastoma . Do not transplant every solid tumor by habit.

Conditioning: intensity and the drugs

Myeloablative conditioning (MAC) uses high-dose chemotherapy with or without total body irradiation (TBI) to empty marrow and, in allogeneic transplants, immunosuppress the host so the graft is not rejected. Reduced-intensity conditioning (RIC) is less marrow-toxic and more immunosuppressive; it is chosen when comorbidity, prior therapy, or protocol design does not support full ablation. RIC is not a "gentle" transplant: mucositis may be milder, but infection, GVHD, and graft failure still happen.

TBI causes mucositis, parotitis, infertility, growth and endocrine injury, cataracts, and secondary-malignancy risk—survivorship language belongs on the roadmap. Attach these chemo agents to a bedside watch:

Busulfan : hepatic sinusoidal obstruction syndrome / veno-occlusive disease (SOS/VOD) risk and seizures from CNS irritability. Give seizure prophylaxis (commonly levetiracetam or another protocol anticonvulsant) through the busulfan window. Many programs use therapeutic drug monitoring. Do not invent a target area-under-the-curve as ONCC fact.

Cyclophosphamide : hemorrhagic cystitis from acrolein— mesna plus hydration as in the chemotherapy chapter; high-dose cyclophosphamide is also cardiotoxic.

Fludarabine : a lymphodepleting nucleoside analog used heavily on RIC and haplo platforms.

Melphalan : severe mucositis; a workhorse in many autologous neuroblastoma regimens.

A 4-year-old receiving busulfan who seizes on day −3 is a missed-prophylaxis event until proven otherwise, not "hospital anxiety."

Engraftment, mucositis, and infection windows

Engraftment is commonly defined as absolute neutrophil count (ANC) recovery —often the first of three consecutive days at or above the protocol threshold (many programs use 500/µL). Platelet independence follows. Teach the concept: donor or rescued autologous neutrophils that can fight bacteria again. Do not treat one printed ANC cutoff as the only ONCC definition.

Mucositis peaks around the nadir and early engraftment after MAC. Opioid analgesia, nutrition support including parenteral nutrition when the mouth and gut cannot keep up, and infection through broken mucosa are expected work.

Infection timing is high-yield:

Pre-engraftment (neutropenic) : bacterial bloodstream and gastrointestinal translocation infections; HSV reactivation; Candida .

Early post-engraftment through about day 100 : cytomegalovirus (CMV) (especially allogeneic, mismatched serostatus), Pneumocystis jirovecii pneumonia without prophylaxis (PCP/PJP), other viruses.

Later, or during prolonged steroids for GVHD : Aspergillus and other molds.

Protective environment, visitor restrictions, masks, and diet (a strict "neutropenic diet" versus food-safety teaching) are institutional . Follow the unit policy. Do not invent a national ONCC rule that no child may ever eat a washed apple.

GVHD prophylaxis and the two timeframes

Allogeneic grafts need GVHD prophylaxis . Common tools: calcineurin inhibitors (cyclosporine, tacrolimus—drug levels, nephrotoxicity, magnesium wasting, posterior reversible encephalopathy risk), methotrexate (adds mucositis and delayed clearance), and PTCy after haploidentical grafts. Autologous transplants do not need GVHD prophylaxis.

Acute GVHD classically involves skin (maculopapular rash, often palms, soles, and ears), gut (secretory diarrhea, cramping, bleeding), and liver (conjugated hyperbilirubinemia). Chronic GVHD is later: sicca (dry eyes and mouth), bronchiolitis obliterans , sclerodermatous skin, fasciitis, and joint contractures. High-level recognition is enough here.

Graft failure, hemorrhagic cystitis, and SOS/VOD as a signpost

Graft failure is failure of ANC recovery in the expected window, or falling counts after brief engraftment with aplasia. In allogeneic transplants think rejection or poor graft function; in autologous transplants think inadequate collection or residual marrow injury. This is a same-day transplant-team call, not "give another day of filgrastim and see."

Hemorrhagic cystitis splits in time: cyclophosphamide (early, acrolein) versus BK virus (later, after engraftment, more often allogeneic). Gross hematuria, clots, and bladder spasm need hydration, platelet support, pain control, and urology—not a wait-and-see pink-urine note.

SOS/VOD presents with tender hepatomegaly , rapid weight gain or ascites, and jaundice . Defibrotide is the disease-directed therapy concept. Fluid, renal, and ultrasound staging live in the later emergency SOS/VOD chapter . Name the triad and the drug here; do not duplicate that algorithm.

A 9-year-old on day +12 after MSD transplant with a new palm rash, eight watery stools, and rising bilirubin has acute GVHD until the team says otherwise. The same child with a tender liver, two kilograms of overnight gain, and jaundice is SOS/VOD until proven otherwise. Those two syndromes are not interchangeable.

The CPHON product is a family that can name auto versus allo and the donor type, a child on busulfan seizure prophylaxis, a nurse who times bacterial versus CMV versus mold risk, and a unit that treats tender hepatomegaly plus weight gain as VOD until the emergency chapter's workup is running.

Loading diagram... HSCT graft type, conditioning, and infection windows